Hany Zayed

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer et al. · The Lancet Oncology · 2016 · 537 citations · Full text

Dll3-targeted Antibody-drug Conjugate, Medicine, Immunology +6

A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial

Andrew W. Bradbury, Catherine A Moakes, Matthew Popplewell et al. · The Lancet · 2023 · 353 citations · Full text

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials

James B. Bussel, Donald M. Arnold, Elliot Grossbard et al. · American Journal of Hematology · 2018 · 329 citations · Full text

Clinical Immunology, Immunodeficiencies, Immunology +19

Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes

Claudia Cavelti‐Weder, Andrea Babians-Brunner, Cornelia Keller et al. · Diabetes Care · 2012 · 301 citations · Full text

The impact of arterial pedal arch quality and angiosome revascularization on foot tissue loss healing and infrapopliteal bypass outcome

Hisham Rashid, Hani Slim, Hany Zayed et al. · Journal of Vascular Surgery · 2013 · 151 citations

Medicine, Peripheral Intervention, Vascular Adaptation +8